Int. J. Mol. Sci. 2019, 20, 5739
15 of 15
7.
8.
9.
Fathi, A.T.; Chen, Y.B. The Role of Flt3 Inhibitors in the Treatment of Flt3-Mutated Acute Myeloid Leukemia.
Eur. J. Haematol. 2017, 98, 330–336. [CrossRef]
Tse, K.F.; Mukherjee, G.; Small, D. Constitutive Activation of Flt3 Stimulates Multiple Intracellular Signal
Transducers and Results in Transformation. Leukemia 2000, 14, 1766–1776. [CrossRef]
Takahashi, S. Downstream Molecular Pathways of Flt3 in the Pathogenesis of Acute Myeloid Leukemia:
Biology and Therapeutic Implications. J. Hematol. Oncol. 2011, 4, 13. [CrossRef]
10. Garcia, J.S.; Stone, R.M. The Development of Flt3 Inhibitors in Acute Myeloid Leukemia. Hematol. Oncol.
Clin. North. Am. 2017, 31, 663–680. [CrossRef]
11. Wu, M.; Li, C.T.; Zhu, X.P. Flt3 Inhibitors in Acute Myeloid Leukemia. J. Hematol. Oncol. 2018, 11, 133–144.
12. Weisberg, E.; Roesel, J.; Furet, P.; Bold, G.; Imbach, P.; Florsheimer, A.; Caravatti, G.; Jiang, J.; Manley, P.;
Ray, A.; et al. Antileukemic Effects of Novel First- and Second-Generation Flt3 Inhibitors: Structure-Affinity
Comparison. Genes Cancer 2010, 10, 1021–1032. [CrossRef]
13. Levis, M. Midostaurin Approved for Flt3-Mutated Aml. Blood 2017, 129, 3403–3406. [CrossRef]
14. Sudhindra, A.; Smith, C.C. Flt3 Inhibitors in Aml: Are We There Yet? Curr. Hematol. Malig. Rep. 2014, 9,
15. Zappone, E.; Defina, M.; Aprile, L.; Bartalucci, G.; Gozzetti, A.; Bocchia, M. Flt3 Inhibitors in the Management
of Acute Myeloid Leukemia. Anti-Cancer Agents Med. Chem. 2017, 17, 1028–1032. [CrossRef]
16. Elshoury, A.; Przespolewski, A.; Baron, J.; Wang, E.S. Advancing Treatment of Acute Myeloid Leukemia:
The Future of Flt3 Inhibitors. Expert Rev. Anticancer Ther. 2019, 19, 273–286. [CrossRef]
17. Dhillon, S. Gilteritinib: First Global Approval. Drugs 2019, 79, 331–339. [CrossRef]
18. Mori, M.; Kaneko, N.; Ueno, Y.; Yamada, M.; Tanaka, R.; Saito, R.; Shimada, I.; Mori, K.; Kuromitsu, S.
Gilteritinib, a Flt3/Axl Inhibitor, Shows Antileukemic Activity in Mouse Models of Flt3 Mutated Acute
Myeloid Leukemia. Investig. New Drugs 2017, 35, 556–565. [CrossRef]
19. Zarrinkar, P.P.; Gunawardane, R.N.; Cramer, M.D.; Gardner, M.F.; Brigham, D.; Belli, B.; Karaman, M.W.;
Pratz, K.W.; Pallares, G.; Chao, Q.; et al. Ac220 Is a Uniquely Potent and Selective Inhibitor of Flt3 for the
Treatment of Acute Myeloid Leukemia (Aml). Blood 2009, 114, 2984–2992. [CrossRef]
20. Malumbres, M.; Barbacid, M. Cell Cycle, Cdks and Cancer: A Changing Paradigm. Nat. Rev. Cancer 2019, 9,
21. Wang, L.; Wang, J.; Blaser, B.W.; Duchemin, A.M.; Kusewitt, D.F.; Liu, T.; Caligiuri, M.A.; Briesewitz, R.
Pharmacologic Inhibition of Cdk4/6: Mechanistic Evidence for Selective Activity or Acquired Resistance in
Acute Myeloid Leukemia. Blood 2007, 110, 2075–2083. [CrossRef]
22. Wang, Y.; Zhi, Y.L.; Jin, Q.M.; Lu, S.; Lin, G.W.; Yuan, H.L.; Yang, T.T.; Wang, Z.W.; Yao, C.; Ling, J.; et al.
Discovery of 4-((7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)Amino)-N-(4-((4-Methylpiperazin-1-Yl)Methyl)Phenyl)-
1H-Pyrazole-3-Carboxamide (Fn-1501), an Flt3- and Cdk-Kinase Inhibitor with Potentially High Efficiency
against Acute Myelocytic Leukemia. J. Med. Chem. 2018, 61, 1499–1518. [CrossRef]
23. Hatcher, J.M.; Weisberg, E.; Sim, T.; Stone, R.M.; Liu, S.Y.; Griffin, J.D.; Gray, N.S. Discovery of a Highly Potent
and Selective Indenoindolone Type 1 Pan-Flt3 Inhibitor. ACS Med. Chem. Lett. 2016, 7, 476–481. [CrossRef]
24. Kiyoi, H. Flt3 Inhibitors: Recent Advances and Problems for Clinical Application. Nagoya J. Med. Sci. 2015,
77, 7–17.
25. Auclair, D.; Miller, D.; Yatsula, V.; Pickett, W.; Carter, C.; Chang, Y.; Zhang, X.; Wilkie, D.; Burd, A.; Shi, H.;
et al. Antitumor Activity of Sorafenib in Flt3-Driven Leukemic Cells. Leukemia 2007, 21, 439–445. [CrossRef]
26. Squires, M.S.; Cooke, L.; Lock, V.; Qi, W.Q.; Lewis, E.J.; Thompson, N.T.; Lyons, J.F.; Mahadevan, D. At7519,
a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines
and Patient Samples. Mol. Cancer Ther. 2010, 9, 920–928. [CrossRef]
27. Yang, W.M.; Chen, Y.D.; Zhou, X.; Gu, Y.Z.; Qian, W.Q.; Zhang, F.; Han, W.; Lu, T.; Tang, W.F. Design,
Synthesis and Biological Evaluation of Bis-Aryl Ureas and Amides Based on 2-Amino-3-Purinylpyridine
Scaffold as Dfg-out B-Raf Kinase Inhibitors. Eur. J. Med. Chem. 2015, 89, 581–596. [CrossRef]
©
2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution